Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Income from Continuing Operations: 2016-2024

Historic Income from Continuing Operations for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2024 value amounting to -$65.6 million.

  • Summit Therapeutics' Income from Continuing Operations fell 81.23% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$183.2 million, marking a year-over-year decrease of 94.97%. This contributed to the annual value of -$234.7 million for FY2024, which is 61.84% up from last year.
  • Latest data reveals that Summit Therapeutics reported Income from Continuing Operations of -$65.6 million as of Q4 2024, which was down 7.88% from -$60.8 million recorded in Q3 2024.
  • In the past 5 years, Summit Therapeutics' Income from Continuing Operations ranged from a high of -$7.4 million in Q1 2020 and a low of -$65.6 million during Q4 2024.
  • Over the past 3 years, Summit Therapeutics' median Income from Continuing Operations value was -$28.4 million (recorded in 2023), while the average stood at -$36.7 million.
  • Data for Summit Therapeutics' Income from Continuing Operations shows a maximum YoY tumbled of 196.86% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Summit Therapeutics' Income from Continuing Operations stood at -$7.4 million in 2020, then reached -$20.3 million in 2022, then crashed by 78.38% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
  • Its Income from Continuing Operations was -$65.6 million in Q4 2024, compared to -$60.8 million in Q3 2024 and -$36.2 million in Q4 2023.